BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 31, 2016--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing CODIT™ (Characterized Oral Desensitization
ImmunoTherapy) treatments for life-threatening food
allergies, today announced that Stephen G. Dilly, M.B.B.S., Ph.D., Chief
Executive Officer of Aimmune, will present a company overview at two
upcoming investor conferences in November as follows:
The 25th Annual Credit Suisse Healthcare Conference on Monday,
November 7, 2016, at 2 p.m. Mountain Time in Scottsdale, Arizona
The 28th Annual Piper Jaffray Healthcare Conference on Tuesday,
November 29, 2016, at 1 p.m. Eastern Time in New York City
The live webcasts of the presentations will be accessible on the Events
page under the Investor Relations section of the Aimmune website at www.aimmune.com.
Archived replays of the webcasts will be available for approximately 30
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), uses
rigorously characterized biologic product candidates with gradual,
controlled up-dosing protocols to obtain clinically meaningful
desensitization to food allergens. Aimmune’s first CODIT product, AR101
for the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005056/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,